Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Onl Therapeutics Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, Sergio Coffa, and is located within 1 distinct art unit. Sergio Coffa is the busiest examiner for the portfolio, overseeing 1 pending office action. This single action constitutes the entirety of the company's active prosecution workload.
The concentration of 1 pending office action under 1 distinct examiner indicates a singular focus for the company's current patent efforts. Sergio Coffa's role as the busiest examiner with 1 pending office action means the company's immediate success in the Biotechnology & Pharmaceuticals field depends on a single review. The presence of 1 distinct art unit confirms that the company's active filings are not distributed across multiple technical groups. This structure provides a direct but narrow path for the company's current intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578663 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578663 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | COFFA, SERGIO | 1658 | §103§112DP | Non-Final OA | — | Pending | Jan 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOnl Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sergio Coffa has the most, with 1 of Onl Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
